Diagnosis of Toxoplasmosis in Immuno-compromised Patients

The molecular division of Diasorin has launched its Iam Toxo. It is the latest addition to the Company’s Q-Lamp assay portfolio for its Liaison Iam molecular instrument, a benchtop device which provides laboratories with a scalable, molecular diagnostic solution.

Toxoplasmosis (Toxo) infection can have severe or fatal consequences for immunocompromised or deficient patients (such as HIV, AIDS, cancer and transplant patients) where infection can result in complications including encephalitis, pulmonary disease and hepatitis and Toxo encephalitis (TE) is a frequent cause of death in AIDS patients.

While serological analysis is widely used for diagnosis of Toxo in immunocompetent individuals, molecular methods are necessary for diagnosis in immunocompromised patients. The diagnostic sensitivity of the assay has been proven to be equivalent to PCR but delivers results produced in a fraction of the time that PCR requires, the Company says.